tetano
Editor, Senior Moderator
Infect Control Hosp Epidemiol
. 2021 Nov 2;1-8.
doi: 10.1017/ice.2021.449. Online ahead of print.
Symptom monitoring after coronavirus disease 2019 (COVID-19) vaccination in a large integrated healthcare system: Separating symptoms from severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection
Erica S Shenoy[SUP] #[/SUP][SUP] 1 2 3 [/SUP], Paige G Wickner[SUP] #[/SUP][SUP] 3 4 [/SUP], Lauren R West[SUP] 1 [/SUP], Aleena Banerji[SUP] 5 [/SUP], Kimberly G Blumenthal[SUP] 3 5 6 [/SUP], Amanda J Centi[SUP] 7 [/SUP], Andrew Gottlieb[SUP] 8 [/SUP], Dean M Hashimoto[SUP] 3 4 8 [/SUP], Esther Kim[SUP] 7 [/SUP], Marvel Kim[SUP] 8 [/SUP], Hang Lee[SUP] 3 9 [/SUP], Lynn A Simpson[SUP] 10 [/SUP], Adam B Landman[SUP] 3 7 11 [/SUP]
Affiliations
Abstract
Objective: To describe the incidence of systemic overlap and typical coronavirus disease 2019 (COVID-19) symptoms in healthcare personnel (HCP) following COVID-19 vaccination and association of reported symptoms with diagnosis of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in the context of public health recommendations regarding work exclusion.
Design: This prospective cohort study was conducted between December 16, 2020, and March 14, 2021, with HCP who had received at least 1 dose of either the Pfizer-BioNTech or Moderna COVID-19 vaccine.
Setting: Large healthcare system in New England.
Interventions: HCP were prompted to complete a symptom survey for 3 days after each vaccination. Reported symptoms generated automated guidance regarding symptom management, SARS-CoV-2 testing requirements, and work restrictions. Overlap symptoms (ie, fever, fatigue, myalgias, arthralgias, or headache) were categorized as either lower or higher severity. Typical COVID-19 symptoms included sore throat, cough, nasal congestion or rhinorrhea, shortness of breath, ageusia and anosmia.
Results: Among 64,187 HCP, a postvaccination electronic survey had response rates of 83% after dose 1 and 77% after dose 2. Report of ≥3 lower-severity overlap symptoms, ≥1 higher-severity overlap symptoms, or at least 1 typical COVID-19 symptom after dose 1 was associated with increased likelihood of testing positive. HCP with prior COVID-19 infection were significantly more likely to report severe overlap symptoms after dose 1.
Conclusions: Reported overlap symptoms were common; however, only report of ≥3 low-severity overlap symptoms, at least 1 higher-severity overlap symptom, or any typical COVID-19 symptom were associated with infection. Work-related restrictions for overlap symptoms should be reconsidered.
. 2021 Nov 2;1-8.
doi: 10.1017/ice.2021.449. Online ahead of print.
Symptom monitoring after coronavirus disease 2019 (COVID-19) vaccination in a large integrated healthcare system: Separating symptoms from severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection
Erica S Shenoy[SUP] #[/SUP][SUP] 1 2 3 [/SUP], Paige G Wickner[SUP] #[/SUP][SUP] 3 4 [/SUP], Lauren R West[SUP] 1 [/SUP], Aleena Banerji[SUP] 5 [/SUP], Kimberly G Blumenthal[SUP] 3 5 6 [/SUP], Amanda J Centi[SUP] 7 [/SUP], Andrew Gottlieb[SUP] 8 [/SUP], Dean M Hashimoto[SUP] 3 4 8 [/SUP], Esther Kim[SUP] 7 [/SUP], Marvel Kim[SUP] 8 [/SUP], Hang Lee[SUP] 3 9 [/SUP], Lynn A Simpson[SUP] 10 [/SUP], Adam B Landman[SUP] 3 7 11 [/SUP]
Affiliations
- PMID: 34726142
- DOI: 10.1017/ice.2021.449
Abstract
Objective: To describe the incidence of systemic overlap and typical coronavirus disease 2019 (COVID-19) symptoms in healthcare personnel (HCP) following COVID-19 vaccination and association of reported symptoms with diagnosis of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in the context of public health recommendations regarding work exclusion.
Design: This prospective cohort study was conducted between December 16, 2020, and March 14, 2021, with HCP who had received at least 1 dose of either the Pfizer-BioNTech or Moderna COVID-19 vaccine.
Setting: Large healthcare system in New England.
Interventions: HCP were prompted to complete a symptom survey for 3 days after each vaccination. Reported symptoms generated automated guidance regarding symptom management, SARS-CoV-2 testing requirements, and work restrictions. Overlap symptoms (ie, fever, fatigue, myalgias, arthralgias, or headache) were categorized as either lower or higher severity. Typical COVID-19 symptoms included sore throat, cough, nasal congestion or rhinorrhea, shortness of breath, ageusia and anosmia.
Results: Among 64,187 HCP, a postvaccination electronic survey had response rates of 83% after dose 1 and 77% after dose 2. Report of ≥3 lower-severity overlap symptoms, ≥1 higher-severity overlap symptoms, or at least 1 typical COVID-19 symptom after dose 1 was associated with increased likelihood of testing positive. HCP with prior COVID-19 infection were significantly more likely to report severe overlap symptoms after dose 1.
Conclusions: Reported overlap symptoms were common; however, only report of ≥3 low-severity overlap symptoms, at least 1 higher-severity overlap symptom, or any typical COVID-19 symptom were associated with infection. Work-related restrictions for overlap symptoms should be reconsidered.